

WEST VIRGINIA LEGISLATURE

2017 REGULAR SESSION

ENROLLED

Senate Bill 188

BY SENATOR TAKUBO

[Passed March 8, 2017; in effect 90 days from passage]



WEST VIRGINIA LEGISLATURE

2017 REGULAR SESSION

ENROLLED

Senate Bill 188

BY SENATOR TAKUBO

[Passed March 8, 2017; in effect 90 days from passage]

AN ACT to amend and reenact §16-5Y-2 of the Code of West Virginia, 1931, as amended, relating
 to clarifying the definition of "telehealth" for purposes of medication-assisted treatment
 programs.

Be it enacted by the Legislature of West Virginia:

1 That §16-5Y-2 of the Code of West Virginia, 1931, as amended, be amended and 2 reenacted to read as follows:

ARTICLE 5Y. MEDICATION-ASSISTED TREATMENT PROGRAM LICENSING ACT. §16-5Y-2. Definitions.

1 (a) "Addiction" means a primary, chronic disease of brain reward, motivation, memory and 2 related circuitry. Dysfunction in these circuits leads to characteristic biological, psychological, 3 social and spiritual manifestations, which is reflected in an individual pathologically pursuing 4 reward or relief by substance use, or both, and other behaviors. Addiction is characterized by inability to consistently abstain; impairment in behavioral control; craving; diminished recognition 5 6 of significant problems with one's behaviors: interpersonal problems with one's behaviors and 7 interpersonal relationships; a dysfunctional emotional response; and as addiction is currently 8 defined by the American Society of Addiction Medicine.

9 (b) "Administrator" means an individual designated by the governing body to be 10 responsible for the day-to-day operation of the opioid treatment programs.

(c) "Advanced alcohol and drug abuse counselor" means an alcohol and drug abuse
 counselor who is certified by the West Virginia Certification Board for Addiction and Prevention
 Professionals who demonstrates a high degree of competence in the addiction counseling field.

(d) "Alcohol and drug abuse counselor" means a counselor certified by the West Virginia
Certification Board for Addiction and Prevention Professionals for specialized work with patients
who have substance use problems.

(e) "Biopsychosocial" means of, relating to or concerned with, biological, psychological
and social aspects in contrast to the strictly biomedical aspects of disease.

(f) "Center for Substance Abuse Treatment" means the center under the Substance Abuse
and Mental Health Services Administration that promotes community-based substance abuse
treatment and recovery services for individuals and families in the community and provides
national leadership to improve access, reduce barriers and promote high quality, effective
treatment and recovery services.

(g) "Controlled Substances Monitoring Program database" means the database
maintained by the West Virginia Board of Pharmacy pursuant to section three, article nine, chapter
sixty-a of this code that monitors and tracks certain prescriptions written or dispensed by
dispensers and prescribers in West Virginia.

(h) "Director" means the Director of the Office of Health Facility Licensure and Certification.
(i) "Dispense" means the preparation and delivery of a medication-assisted treatment
medication in an appropriately labeled and suitable container to a patient by a medication-assisted
treatment program or pharmacist.

(j) "Governing body" means the person or persons identified as being legally responsible
for the operation of the opioid treatment program. A governing body may be a board, a single
entity or owner, or a partnership. The governing body must comply with the requirements
prescribed in rules promulgated pursuant to this article.

36 (k) "Medical director" means a physician licensed within the State of West Virginia who 37 assumes responsibility for administering all medical services performed by the medication-38 assisted treatment program, either by performing them directly or by delegating specific 39 responsibility to authorized program physicians and health care professionals functioning under 40 the medical director's direct supervision and functioning within their scope of practice.

(I) "Medication-assisted treatment" means the use of medications and drug screens, in
combination with counseling and behavioral therapies, to provide a holistic approach to the
treatment of substance use disorders.

Enr. SB 188

(m) "Medication-assisted treatment program" means all publicly and privately owned
opioid treatment programs and office based medication-assisted treatment programs, which
prescribe medication-assisted treatment medications and treat substance use disorders, as those
terms are defined in this article.

(n) "Medication-assisted treatment medication" means any medication that is approved by
the United States Food and Drug Administration under Section 505 of the Federal Food, Drug
and Cosmetic Act, 21 U. S. C. § 355, for use in the treatment of substance use disorders that is
an opioid agonist and is listed on the schedule of controlled substances in article two, chapter
sixty-a of this code.

(o) "Office based medication-assisted treatment" means all publicly or privately owned medication-assisted treatment programs in clinics, facilities, offices or programs that treat individuals with substance use disorders through the prescription, administration or dispensing of a medication-assisted treatment medication in the form of a partial opioid agonist or other medication-assisted medication approved for use in office-based, medication-assisted treatment setting.

(p) "Opioid agonist" means substances that bind to and activate the opiate receptors
resulting in analgesia and pain regulation, respiratory depression and a wide variety of behavioral
changes. As used in this article, the term "opioid agonist" does not include partial agonist
medications used as an alternative to opioid agonists in the treatment of opioid addiction.

(q) "Opioid treatment program" means all publicly or privately owned medication-assisted
treatment programs in clinics, facilities, offices or programs that treat individuals with substance
use disorders through on-site administration or dispensing of a medication-assisted treatment
medication in the form of an opioid agonist or partial opioid agonist.

67 (r) "Owner" means any person, partnership, association or corporation listed as the owner
68 of a medication-assisted treatment program on the licensing or registration forms required by this
69 article.

Enr. SB 188

(s) "Partial opioid agonist" means a Federal Drug Administration approved medication that
is used as an alternative to opioid agonists for the treatment of substance use disorders and that
binds to and activates opiate receptors, but not to the same degree as full agonists.

(t) "Physician" means an individual licensed in this state to practice allopathic medicine or
surgery by the West Virginia Board of Medicine or osteopathic medicine or surgery by the West
Virginia Board of Osteopathic Medicine and that meets the requirements of this article.

(u) "Prescriber" means a person authorized in this state, working within their scope of
practice, to give direction, either orally or in writing, for the preparation and administration of a
remedy to be used in the treatment of substance use disorders.

(v) "Program sponsor" means the person named in the application for the certification and licensure of an opioid treatment program who is responsible for the administrative operation of the opioid treatment program and who assumes responsibility for all of its employees, including any practitioners, agents or other persons providing medical, rehabilitative or counseling services at the program.

(w) "Secretary" means the Secretary of the West Virginia Department of Health andHuman Resources or his or her designee.

(x) "State opioid treatment authority" means the agency or individual designated by the
 Governor to exercise the responsibility and authority of the state for governing the treatment of
 substance use disorders, including, but not limited to, the treatment of opiate addiction with opioid
 drugs.

(y) "State oversight agency" means the agency or office of state government identified by
the secretary to provide regulatory oversight of medication-assisted treatment programs on behalf
of the State of West Virginia.

93 (z) "Substance" means the following:

94 (1) Alcohol;

95 (2) Controlled substances defined by sections two hundred four, two hundred six, two
96 hundred eight, and two hundred ten, article two, chapter sixty-a of this code; or

97 (3) Any chemical, gas, drug or medication consumed which causes clinically and 98 functionally significant impairment, such as health problems, disability and failure to meet major 99 responsibilities at work, school or home.

(aa) "Substance Abuse and Mental Health Services Administration" means the agency
under the United States Department of Health and Human Services responsible for the
accreditation and certification of medication-assisted treatment programs and that provides
leadership, resources, programs, policies, information, data, contracts and grants for the purpose
of reducing the impact of substance abuse and mental or behavioral illness.

(bb) "Substance use disorder" means patterns of symptoms resulting from use of a
substance that the individual continues to take, despite experiencing problems as a result; or as
defined in the most recent edition of the American Psychiatric Association's Diagnostic and
Statistical Manual of Mental Disorders.

(cc) "Telehealth" means the mode of delivering health care services and public health via
information and communication technologies to facilitate the diagnosis, consultation, treatment
education, care management and self-management of a patient's health care while the patient is
at the originating site and the health care provider is at a distant site.

(dd) "Variance" means written permission granted by the secretary to a medicationassisted treatment program that a requirement of this article or rules promulgated pursuant to this article may be accomplished in a manner different from the manner set forth in this article or associated rules.

(ee) "Waiver" means a formal, time-limited agreement between the designated oversight
agency and the medication-assisted treatment program that suspends a rule, policy or standard
for a specific situation so long as the health and safety of patients is better served in the situation
by suspension of the rule, policy or standard than by enforcement.

The Joint Committee on Enrolled Bills hereby certifies that the foregoing bill is correctly_enrolled. Chairman, Senate Committee 2011 WAR Chairman, House Committee ω D Originated in the Senate. 4:43 In effect 90 days from passage, Clerk of the Senate Clerk of the House of Delegates President of the Senate Speaker of the House of Delegates 11 approvel .. this the.....1344 The within Day of 2017. lll Governor--->

PRESENTED TO THE GOVERNOR

MAR 1 0 2017

2:54 pm

ļ